CaryMiller Ph.D.

With more than 15 years of experience, Dr. Cary Miller's practice focuses on assisting life sciences clients with their patent issues. She works with clients in patent prosecution, prelitigation analysis, PTAB proceedings, and patent litigation.

Cary currently represents Celgene in several Hatch-Waxman patent litigations involving the pharmaceuticals Abraxane®, Pomalyst®, and Revlimid®. Prior to joining Jones Day, Cary participated in numerous biotechnology and pharmaceutical patent lawsuits, including representing companies in Hatch-Waxman litigation, biosimilars litigation (Biologics Price Competition and Innovation Act [BPCIA]), and in litigation relating to DNA sequencing. She has successfully litigated patent cases throughout the United States, including in California, New Jersey, New York, Delaware, Texas, and Nevada and before the Federal Circuit and Supreme Court.

Cary has drafted and prosecuted patents relating to breakthrough therapies in a number of areas, including antibodies and antibody-drug conjugates, cancer therapeutics and diagnostics, small molecules, human embryonic stem cells, and drug delivery devices. She has conducted intellectual property due diligence studies and has filed numerous patent term extension applications for drugs, biologics, and medical devices.

Cary holds a Ph.D. in cellular, developmental, and molecular biology. She writes extensively on PTAB proceedings and on biologics and biosimilars. Her scientific articles appeared in Nature Genetics, Development, Mechanisms of Development, Journal of Cell Biology, and the American Journal of Human Genetics. She also coauthored a book chapter in The Endometrium.